May 23 (Reuters) - Prometic Life Sciences Inc PLI.TO :
* Prometic presents new data on PBI-4050 and plasminogen at American Thoracic Society's 2017 international conference
* Prometic Life Sciences Inc - PBI-4050 + nintedanib provided a statistically significant benefit over pbi-4050 + pirfenidone
* Prometic Life Sciences - intends to initiate a second phase 2/3 placebo-controlled trial in which IPF patients who failed to tolerate either nintedanib or pirfenidone
* Prometic Life Sciences Inc - Prometic plans to initiate both studies in second half of 2017. Source text for Eikon: ID:nPn74BpXsa Further company coverage: PLI.TO